Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5629MR)

This product GTTS-WQ5629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5629MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14005MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ593MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ3748MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ10299MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ8617MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ11021MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ2853MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ10059MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW